“…Recently, in our ongoing research on immunomodulatory substances, we reported the pharmacological development of the non-natural 1,2- O -distearoyl-3- O -β- d -sulfoquinovosylglycerol, here named Sulfavant A ( 1 ) ( Figure 1 ), as a prototype for a new class of molecular adjuvants based on a sulfolipid skeleton [ 4 ]. This family of products is structurally inspired by the natural α- d -sulfoquinovosyl-diacylglycerols (α-SQDG), bioactive metabolites bearing a 6-sulfonic function on d -glucose (sulfoquinovose) linked to a glycerol moiety with two fatty acyl chains [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ]. The natural sulfoglycoglycerolipids are marked by the α-configuration of the anomeric carbon and the β-configuration type is not present in nature.…”